fda compounded semaglutide enforcement news The is drawing a harder line on weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA On February 21, 2025, the

Great product and company

doi: 10.1016/j.phymed.2010.06.004 141 LeeYJLeeYMLeeCKJungJKHanSBHongJTet al

Tirzepatide is superior for weight loss and HbA1c endpoints

: ( ), ,

Among those subscribers, nearly 1.5 million collaborated with a provider to receive a personalized treatment, up 89% year over year, co-founder and CEO Andrew Dudum told investors on the company's second-quarter earnings call

Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants with Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data from the SCALE Clinical Development Program